OKURHIGH SIGNALRISK10-K

Management has concluded that substantial doubt exists as to the company's ability to continue as a going concern, while cash reserves plummeted 47% to $59M.

The addition of going concern qualification language represents a material escalation in financial risk, indicating management believes the company may not survive without additional funding or dramatic operational changes. Combined with the severe cash burn and deteriorating operating losses, this suggests OKUR faces an imminent liquidity crisis that could threaten its existence as an independent entity.

Comparing 2026-03-12 vs 2025-03-10View on EDGAR →
FINANCIAL ANALYSIS

OKUR experienced severe financial deterioration with cash and equivalents dropping 47% to $59M while operating losses worsened 16% to $63M, driven primarily by a 10% increase in R&D spending to $48.3M. The company's balance sheet contracted dramatically with total assets declining 46% to $62.1M and stockholders' equity falling proportionally to $56.2M. This financial picture, combined with the new going concern qualification, signals a company rapidly burning through its remaining capital with deteriorating operational performance.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
-46.7%
$110.8M$59.0M

Cash declined 46.7% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Total Liabilities
Balance Sheet
-46.4%
$11.1M$5.9M

Liabilities reduced 46.4% — deleveraging improves balance sheet strength and financial flexibility.

Current Assets
Balance Sheet
-46.2%
$113.0M$60.8M

Current assets declined 46.2% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-45.9%
$114.9M$62.1M

Total assets contracted 45.9% — asset sales, write-downs, or balance sheet optimization underway.

Stockholders Equity
Balance Sheet
-45.9%
$103.8M$56.2M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Current Liabilities
Balance Sheet
-43.8%
$10.5M$5.9M

Current liabilities reduced — improved short-term financial position and working capital health.

Operating Income
P&L
-15.7%
-$54.4M-$63.0M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

Net Income
P&L
-13%
-$52.7M-$59.5M

Net income declined 13% — review whether driven by operations, interest costs, or non-recurring items.

R&D Expense
P&L
+10.2%
$43.8M$48.3M

R&D investment increased 10.2% — signals commitment to future product development, though near-term margin impact.

LANGUAGE CHANGES
NEW — 2026-03-12
PRIOR — 2025-03-10
ADDED
As of March 11, 2026, the registrant had 13,673,565 shares of Class A common stock, $0.0001 par value per share outstanding.
Our management has concluded that substantial doubt exists as to our ability to continue as a going concern.
Using a structure-based drug design platform, we are committed to improving clinical outcomes for patients by building a pipeline of small molecule drugs designed to achieve optimal efficacy and tolerability by selectively targeting specific mutations shown to be key drivers of cancer and other diseases.
By selectively sparing the wild-type enzyme and preferentially targeting the mutated form of the protein, which is oncogenic and drives disease processes in both cancer and vascular overgrowth syndromes, we aim to discover and develop drugs with improved safety and efficacy by sparing toxicity that arises from non-selective inhibition of the non-mutated (or wild-type) version of the protein.
We designed our current product candidates utilizing disciplined medicinal chemistry, x-ray crystallography and computational chemistry to inhibit specified mutated versions of phosphoinositide 3-kinase alpha ( PI3K ), a key disease creating gene.
+7 more — sign up free →
REMOVED
As of March 7, 2025, the registrant had 12,749,299 shares of Class A common stock, $0.0001 par value per share, and 686,527 shares of Class B common stock, $0.0001 par value per share, outstanding.
Form 10-K Summary 150 2 Explanatory Note On October 4, 2024 (the "Closing Date"), the Delaware corporation formerly known as Reneo Pharmaceuticals, Inc.
("Reneo") completed its previously announced merger transaction pursuant to the terms of the Agreement and Plan of Merger, dated as of May 10, 2024 (the "Merger Agreement"), by and among Reneo, Radiate Merger Sub I, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of Reneo ("Merger Sub I"), Radiate Merger Sub II, LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of Reneo ("Merger Sub II"), and OnKure, Inc., a Delaware corporation ("Legacy OnKure").
Pursuant to the Merger Agreement, on the Closing Date, (i) Reneo effected a reverse stock split of Reneo s issued common stock at a ratio of 1:10 (the "Reverse Stock Split"), (ii) Reneo changed its name to OnKure Therapeutics, Inc.
, (iii) Reneo reclassified all of its common stock as Class A Common Stock or Class B Common Stock, and (iv) Merger Sub I merged with and into Legacy OnKure (the "Merger"), with Legacy OnKure as the surviving company in the Merger and, after giving effect to such Merger, Legacy OnKure became a wholly-owned subsidiary of OnKure Therapeutics, Inc.
+7 more — sign up free →
MORE RISK SIGNALS
CAPSHIGHCAPS underwent a major business expansion through acquisitions while experiencin...
2026-04-16
KALAHIGHKALA has undergone a dramatic business transformation with massive share dilutio...
2026-04-15
RAINHIGHRain Enhancement Technologies underwent a financial restatement revealing signif...
2026-04-15
POLAHIGHPOLA experienced severe financial deterioration with gross profit turning negati...
2026-04-15
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →